Pfizer Inc. Sutent

La Jolla, New York, March 13: Pfizer Inc. announced on Thursday that the company has halted a phase 3 clinical trial of its cancerdefine drug Sutent after the drug was found effective in treatment of advanced pancreatic islet cell tumors.

Evaluating the effectiveness of its drug Sutent (sunitinib malate), the company said it slowed the progression of rare pancreatic cancerdefine, also known as pancreatic neuroendocrine tumor.

The independent data monitoring committee recommended pharmaceutical giant Pfizer Inc. (nyse: PFE-news-people) to end the trial mid way as the drug proved more helpful in halting the progression of pancreatic cancer than placebo and other supportive treatment.